Inclusion Criteria:

- Patient with unresectable locoregional recurrence of squamous cell carcinoma in a
previously irradiated area (at least 75% of the volume of recidivism must be in an
area who have received at least 50 Gy)

- The entire tumor volume can be included in a radiation field without the total dose
to the spinal cord more than 50 Gy (dose + dose earlier predicted)

- Patient with recurrent or second location in the oral cavity, oropharynx, larynx,
hypopharynx, cervical lymph nodes or tissues, without distant metastases,

- Minimum 12 months after the end of radiotherapy previous

- WHO performance status: 0-1,

- Evaluable disease by RECIST V.1.1.,

- Age between 18 and 75 years

- The patient may have received prior chemotherapy for relapse for more than five
weeks,

- The patient may have received cetuximab for the treatment of disease but not for the
first relapse,

- Hematologic function: ANC ≥ 1500/mm3, Platelets ≥ 100000/mm3,

- Normal renal function: serum creatinine ≤ 120 µmol/l and/or creatinine clearance > 60
ml/min

- Normal liver function: bilirubin <1.5 x ULN, alkaline phosphatase and transaminases
<2.5 x ULN,

- Normal cardiac function, assessed clinically. History of cardiovascular disease
stabilized for over 12 months

- Cons-Lack of medical indications in the proposed treatment,

- The dosimetry of previous treatment should be available and the estimated dosimetry
must be performed to check the constraints,

- All patients of childbearing age should receive effective contraception,

- Membership of a social security system (or be a beneficiary of such a plan) under the
terms of the Act of August 9, 2004,

- Signed informed consent

Exclusion Criteria:

- Tumors of the nasal cavity and paranasal,

- Tumors of other histological type,

- Stage IV with distant metastases or multiple tumors,

- Time after previous radiotherapy <12 months,

- Less than 75% of the volume of relapse who have previously received at least 50 Gy,

- Any medical condition or general-cons would indicate the completion of treatment.
Systemic disease or uncontrolled infection,

- History of cancer other than head and neck cancer, cutaneous basal cell, carcinoma in
situ of the cervix

- Any other concurrent anticancer therapy,

- Patient receiving another molecule experimental

- Pregnant, lactating or without contraception;

- Persons deprived of liberty under guardianship

- Inability to undergo medical test for geographical, social or psychological

- Nasopharyngeal Neoplasms

- Patients with active ischemic heart disease or previous myocardial infarction within
the last 12 months

- Late toxicity dermal or subcutaneous related to previous irradiation of grade> 2 in
the scale CTCAE V.4.